Table 3.
Summary of pharmacokinetic parameters from the in vivo study of GL (mean ± standard deviation, n=5)
| Formulation | Cmax (μg/mL) | Tmax (hours) | AUC0–24 (μg/mL/hour) | F* |
|---|---|---|---|---|
| GL-PL/SDC-MMs | 28.33a±2.38 | 0.51±0.11 | 107.33a±9.54 | 2.61 |
| Dried powder containing GL-HPMC50 | 28.09a±3.11 | 0.49±0.13 | 95.37a±8.44 | 2.32 |
| Dried powder containing GL-TPGS10-HPMC30 | 30.12a±3.87 | 0.50±0.09 | 123.01a±10.21 | 2.99 |
| Control group | 7.88±0.94 | 0.50±0.08 | 41.18±4.92 |
Notes:
a
P<0.05 versus control group
*
relative bioavailability when compared with control group.
Abbreviations: AUC0–24, area under the curve during 24 hours; GL, glycyrrhizin; PL, phospholipid; HPMC, hydroxypropyl methyl cellulose; TPGS, alpha-D-tocopherol polyethylene glycol 1000 succinate; MMs, mixed micelles; SDC, sodium deoxycholate; Cmax, peak plasma concentration; Tmax, time taken to reach peak plasma concentration.